Featured News
671Wire StoriesACT Games Reveals Promotion Video for ZOIDS WILD NFT ARENA: the First NFT Game Using ZOIDS WILD Franchise
– An NFT game that utilizes ZOIDS WILD and ZOIDS WILD ZERO, popular iterations of the ZOIDS franchise, to be released later...
- 589Wire Stories
Vietnam Rice Industry Report 2022-2031: Development Environment, Supply and Demand, Import and Export, Market Competition, Major Companies, Outlook – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Research Report on Vietnam’s Rice Industry 2022-2031” report has been added to ResearchAndMarkets.com’s offering. Vietnam is rich in rice, tropical...
- 585Wire Stories
upGrad Closes Investment Round of USD 210 Million
MUMBAI, India–(BUSINESS WIRE)–#ACC–upGrad, Asia’s higher edtech major, has announced a fresh round of fundraise from marquee investors and Family Offices who join...
- 574Wire Stories
Zai Lab Partner Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia
Trial met primary endpoint, with KarXT demonstrating a statistically significant 9.6-point reduction in PANSS Total Score compared to placebo at Week 5...
- 612Wire Stories
Cyclo Therapeutics to Present at the China NPC Association Meeting
GAINESVILLE, Fla.–(BUSINESS WIRE)–Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines...
- 541Wire Stories
Plastec Technologies Reports Fiscal 2022 First Half Results; Announces Extension of Securities Repurchase Plan
HONG KONG–(BUSINESS WIRE)–Plastec Technologies, Ltd. (OTCBB: PLTYF) (the “Company”) today reported unaudited financial results for the six months ended June 30, 2022....
- 639Wire Stories
HERTHENA-Lung02 Phase 3 Trial of Patritumab Deruxtecan Initiated in Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer
TOKYO & BASKING RIDGE, N.J.–(BUSINESS WIRE)–Daiichi Sankyo (TSE: 4568) announced today that the first patient has been dosed in the global HERTHENA-Lung02...
- 555Wire Stories
Review of SURPASS-ET Trial Evaluating Ropeginterferon Alfa-2b-njft for Essential Thrombocythemia (ET) Published in Future Oncology
Pivotal study will offer insights on the effectiveness of a unique monopegylated interferon as an alternative to currently available options for people...
- 577Wire Stories
China Aflibercept Market Investigation Report 2022-2031 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Investigation Report on China’s Aflibercept Market 2022-2031” report has been added to ResearchAndMarkets.com’s offering. Aflibercept is an anti-VEGF drug, mainly...
- 591News
“hello Summer Privileges” welcomes 2nd phase of Consumption Voucher Scheme
Extension of Lucky Draw Rewards with Prizes worth over HK$2.5 million and extra hello points Customers with designated spending will get additional...
- 536Wire Stories
Radware Reports Second Quarter 2022 Financial Results
Second Quarter 2022 Results and Financial Highlights Revenue of $75.1 million, up 8% year–over–year Total ARR of $195 million, up 10% year-over-year...
